# US 2008/0187575 A1 · Pyrimidine Derivatives

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0187575 A1
- Document ID: US20080187575A1
- Status: Published application
- Kind: A1
- Application number: 11/661,041
- Filed: 2005-08-29
- Published: 2008-08-07
- Earliest claimed: 2004-08-27
- Inventors: Bert Klebl; Matthias Baumann; Edmund Hoppe; Dirk Brehmer; Henrik Daub; Gyorgy Keri; Zoltan Varga; Jeno Marosfalvi; Laszlo Orfi
- Web page: https://patentgrep.com/patent/US20080187575A1

## CPC

- C07D 239/42: One nitrogen atom (nitro radicals C07D239/30)
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 7/08: Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock (artificial tears A61P27/04)
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/12: Antihypertensives
- A61P 9/14: Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/06: Antiasthmatics
- A61P 13/10: of the bladder
- A61P 13/12: of the kidneys
- A61P 15/10: for impotence
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/06: for tuberculosis
- A61P 31/12: Antivirals
- A61P 31/18: for HIV
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07D 401/10: linked by a carbon chain containing aromatic rings
- C07D 401/14: containing three or more hetero rings
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to pyrimidine derivatives, methods for their synthesis, and the use of said pyrimidine derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of cell proliferation disorders, cancer, leukemia, erectile dysfunction, cardiovascular diseases and disorders, inflammatory diseases, transplant rejection, immunological diseases, neuroimmunological diseases, autoimmune diseases, infective diseases including opportunistic infections, prion diseases and/or neuro-degeneration. Furthermore, the present invention relates to pharmaceutical compositions containing at least one pyrimidine derivative and/or pharmaceutically acceptable salts thereof as an active ingredient together with at least one pharmaceutically acceptable carrier, excipient or diluents as well as to methods for prophylaxis and/or treatment of the above-mentioned diseases and disorders.

## Claims

### Claim 1

A compound of formula (I):
wherein:
R and R* represent independently of each other —H, —OCH3, —CF3, —CH3, —C2H5, —R′, —R17;
R′, R″, R′″ and R″″ represent independently of each other —H, —F, —Cl, —Br, —I, —CN, —OH, —OCH3, —OC2H5, —OCF3, —NH2, —NO2, —N(CH3)2, —N(C2H5)2, —SH, —SO3H, —COOH, —COOCH3, —COOC2H5, —CONH2;
R1, R2, R3, R4, R1′, R2′, and R3′ represent independently of each other —H, —R′, —OH, —SH, —OCH3, —OC2H5, —SCH3, —NH2, —NO2, —NH(CH3), —N(CH3)2, —COOH, —COOCH3, —OCF3, —CH3, —C2H5, —C3H7, —CH(CH3)2, —R12,
R5 represents —H, —R4, —CH2R3, —C2H4R3, —C3H6R3, —C4H8R3, —CHR3R4, —CH2—CHR3R4, —C2H4—CHR3R4, —C3H6—CHR3R4, —R11, —R13,
R6, R7, R8 and R9 represent independently of each other —H, —R′, —R1, —CH2R1, —R12;
R10, R11, R17, R18 and R19 represent independently of each other —H, —R′, —CH3, —C2H5, —CH═CH2, —C≡CH, —C3H7, -cyclo-C3H5, —CH(CH3)2, —CH2—CH═CH2, —C(CH3)═CH2, —CH═CH—CH3, —C≡C—CH3, —CH2—C≡CH, —C4H9, -cyclo-C4H7, —CH2—CH(CH3)2, —CH(CH3)—C2H5, —C(CH3)3, —C5H11, -cyclo-C5H9, —C6H13, -cyclo-C6H11, -Ph, —C(R′)3, —CR′(R″)2, —CR′(R″)R′″, —C2(R′)5, —CH2—C(R′)3, —CH2—CR′(R″)2, —CH2—CR′(R″)R′″, —C3(R′)7, —C2H4—C(R′)3, —CH(R′)—CH(R″)—CH2—R′″, —CH2—R′, —C2H4—R′, —C3H6—R′, —C4H8—R′, —C5H10—R′, —C6H12—R′;
R12 and R13 represent independently of each other —H, —F, —Cl, —Br, —I, —CH2F, —CH2Cl, —CH2Br, —CH2I, —CH2R3, —OH, —OCH3; —OC2H5, —NH2, —NH(CH3), —N(CH3)2, —N(C2H5)2, —OCF3, —CH3, —C2H5, —C3H7, —R1O, —NH(R10), —NH(R11), —N(R10)2, —NR10R11, —OR10, —OR11, —CO—R10, —COOH, —COOCH3, —COOC2H5, —COOR10, —OOCR10, —SO3H, —SO3R10, —SO2H, —SO2R10, —SO2—CH3, —CO—CH3, —OOC—CH3, —OOC—C2H5, —CONH2, —CONH(R10), —CON(R10)2, —CONR10R11, —NH—CO—R10, —NH—CO—CH3, —NH—CO—C2H5, —NH—CO—C(CH3)3, —NH—CO—OCH3, —NH—CO—NH2;
R14 and R15 represent independently of each other —H, —R1′, —F, —Cl, —Br, —I, —CH2F, —CH2Cl, —CH2Br, —CH2I, —CH2R3, —OH, —OCH3, —OC2H5, —NH2, —NH(CH3), —N(CH3)2, —N(C2H5)2, —OCF3, —CH3, —C2H5, —C3H7, —R18, —NH(R18), —NH(R19), —N(R18)2, —NR18R19, —OR18, —CO—R18, —COOH, —COOCH3, —COOC2H5, —COOR18, —OOCR18, —SO3H, —SO3R18, —SO2H, —SO2R18, —SO2—CH3, —CO—CH3, —OOC—CH3, —OOC—C2H5, —CONH2, —CONH(R18), —CON(R18)2, —CONR18R19, —NH—CO—R18, —NH—CO—CH3, —NH—CO—C2H5, —NH—CO—C(CH3)3, —NH—CO—OCH3, —NH—CO—NH2, —CR1′(R2′)R3′, —CH2—CR1′(R2′)R3′, —CHR1′—CH2R2′, —CH(R1′)—CH(R2′)—CH2—R3′, —CH2—R1′, —C2H4—R1′, —C3H6—R1′, —C4H8—R1′, —C5H10—R1′, —C6H12—R1′;
X represents
Z represents —NH—CO—R5, —CO—NH—R5, —NH—CS—R5, —NH—SO2—R5, —NH2, —NO2, —OCH3, —SCH3, —CF3, —COOH, —COOCH3, —COOC2H5,
and/or pharmaceutically acceptable salts thereof;
and wherein the following compounds are excluded:
1-(4-{4-[4-(4-Imidazol-1-ylphenyl)-pyrimidin-2-ylamino]-benzoyl}-piperazin-1-yl)ethanone,
4-[4-(4-Imidazol-1-ylphenyl)-pyrimidin-2-ylamino]-benzamide,
2-(3-Fluorophenylamino)-4-(4-imidazol-1-ylphenyl)-pyrimidine-5-carbonitrile.

### Claim 2 (depends on 1)

The compound according to claim 1, wherein the compound has the formula (Ic):
wherein
Z′ is

### Claim 3 (depends on 1)

The compound according to claim 1, wherein the compound has the formula (Ih):
wherein Z′″ represents —R1, —R5, and —R13, provided that Z′″ is not —H or CnH2n+1 with n being an integer between 1 and 6.

### Claim 4 (depends on 1)

The compound according to claim 1, wherein the compound has the formula (In):
wherein
Z′ is

### Claim 5 (depends on 1)

The compound according to claim 1, wherein the compound has the formula (Io):
wherein Y represents the residue —C(═O)— or —SO2—, and X′ represents 2-pyridyl or 4-pyridyl.

### Claim 6 (depends on 1)

The compound according to claim 1, wherein the compound is selected from the group consisting of:
Compound 58 [4-(4-Imidazol-1-yl-phenyl)-pyrimidin-2-yl]-(2-methyl-5-nitro-phenyl)-amine;
Compound 93 4-Cyano-N-[4-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-benzamide;
Compound 96 Naphthalene-2-carboxylic acid [4-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-amide;
Compound 97 N-(4-Pyridin-2-yl-pyrimidin-2-yl)-benzene-1,4-diamine;
Compound 98 3,4,5-Trimethoxy-N-[4-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-benzamide;
Compound 99 Thiophene-2-sulfonic acid [4-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-amide;
Compound 100 2-Methoxy-N-[4-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-benzamide;
Compound 101 4-Methyl-N-[4-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-benzamide;
Compound 102 [1,6]Naphthyridine-2-carboxylic acid [3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-amide;
Compound 103 N-(4-Pyridin-4-yl-pyrimidin-2-yl)-benzene-1,4-diamine;
Compound 104 [1,6]Naphthyridine-2-carbothioic acid [3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-amide;
Compound 105 4-Cyano-N-[4-(4-pyridin-4-yl-pyrimidin-2-ylamino)-phenyl]-benzamide;
Compound 106 4-Chloromethyl-N-[4-(4-pyridin-4-yl-pyrimidin-2-ylamino)-phenyl]-benzamide;
Compound 107 4-Chloromethyl-N-[4-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-benzamide;
Compound 108 4-(4-Methyl-piperazin-1-ylmethyl)-N-[4-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-benzamide;
Compound 109 4-Chloro-N-[4-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-benzamide;
Compound 110 Naphthalene-2-carboxylic acid [4-(4-pyridin-2-yl-pyrimidin-2-ylamino)-phenyl]-amide;
Compound 111 3,4,5-Trimethoxy-N-[4-(4-pyridin-2-yl-pyrimidin-2-ylamino)-phenyl]-benzamide;
Compound 112 N-[4-(4-Pyridin-2-yl-pyrimidin-2-ylamino)-phenyl]-4-trifluoromethoxy-benzamide;
Compound 113 4-Chloro-N-[4-(4-pyridin-2-yl-pyrimidin-2-ylamino)-phenyl]-benzamide;
Compound 114 2-Methoxy-N-[4-(4-pyridin-2-yl-pyrimidin-2-ylamino)-phenyl]-benzamide;
Compound 115 4-Methyl-N-[4-(4-pyridin-2-yl-pyrimidin-2-ylamino)-phenyl]-benzamide;
Compound 116 Thiophene-2-sulfonic acid [4-(4-pyridin-2-yl-pyrimidin-2-ylamino)-phenyl]-amide;
Compound 117 N-[4-(4-Pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-4-trifluoromethoxy-benzamide;
Compound 118 N-[4-(4-Pyridin-2-yl-pyrimidin-2-ylamino)-phenyl]-nicotinamide;
Compound 119 Thiophene-2-carboxylic acid [4-(4-pyridin-2-yl-pyrimidin-2-ylamino)-phenyl]-amide;
Compound 120 N-[4-(4-Pyridin-4-yl-pyrimidin-2-ylamino)-phenyl]-benzamide;
Compound 121 N-[4-(4-Pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-nicotinamide;
Compound 122 4-Methoxy-N-[4-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-benzamide;
Compound 123 3,5-Dimethoxy-N-[4-(4-pyridin-2-yl-pyrimidin-2-ylamino)-phenyl]-benzamide;
Compound 124 3,5-Dimethoxy-N-[4-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-benzamide;
Compound 125 2-Chloro-N-[4-(4-pyridin-4-yl-pyrimidin-2-ylamino)-phenyl]-acetamide;
Compound 126 2-Chloro-N-[4-(4-pyridin-2-yl-pyrimidin-2-ylamino)-phenyl]-acetamide;
Compound 127 2-Chloro-N-[4-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-acetamide;
Compound 128 2-Chloro-N-[3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-acetamide;
Compound 129 2-Chloro-N-[3-(4-pyridin-4-yl-pyrimidin-2-ylamino)-phenyl]-acetamide;
Compound 130 2-Chloro-N-[3-(4-pyridin-2-yl-pyrimidin-2-ylamino)-phenyl]-acetamide;
Compound 131 2-(4-Methyl-piperazin-1-yl)-N-[3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-acetamide;
Compound 132 N*3*-[4-(4-Imidazol-1-yl-phenyl)-pyrimidin-2-yl]-4-methyl-benzene-1,3-diamine;
Compound 133 4-Chloro-N-{3-[4-(4-imidazol-1-yl-phenyl)-pyrimidin-2-ylamino]-4-methyl-phenyl}-benzamide;
Compound 134 N-{3-[4-(4-Imidazol-1-yl-phenyl)-pyrimidin-2-ylamino]-4-methyl-phenyl}-4-methyl-benzamide;
Compound 135 [4-(4-Imidazol-1-yl-phenyl)-pyrimidin-2-yl]-(3-nitro-phenyl)-amine;
Compound 136 N-{3-[4-(4-Imidazol-1-yl-phenyl)-pyrimidin-2-ylamino]-4-methyl-phenyl}-3,4,5-trimethoxy-benzamide;
Compound 137 4-Cyano-N-{3-[4-(4-imidazol-1-yl-phenyl)-pyrimidin-2-ylamino]-4-methyl-phenyl}-benzamide;
Compound 138 N-{3-[4-(4-Imidazol-1-yl-phenyl)-pyrimidin-2-ylamino]-4-methyl-phenyl}-nicotinamide;
Compound 139 Thiophene-2-sulfonic acid {3-[4-(4-imidazol-1-yl-phenyl)-pyrimidin-2-ylamino]-4-methyl-phenyl}-amide;
Compound 140 Naphthalene-2-carboxylic acid {3-[4-(4-imidazol-1-yl-phenyl)-pyrimidin-2-ylamino]-4-methyl-phenyl}-amide;
Compound 141 N-{3-[4-(4-Imidazol-1-yl-phenyl)-pyrimidin-2-ylamino]-4-methyl-phenyl}-2-methoxy-benzamide;
Compound 142 N-[4-(4-Imidazol-1-yl-phenyl)-pyrimidin-2-yl]-benzene-1,3-diamine;
Compound 143 N,N′-Bis-[4-(4-imidazol-1-yl-phenyl)-pyrimidin-2-yl]-benzene-1,3-diamine;
Compound 144 [4-(3,4-Dimethoxy-phenyl)-pyrimidin-2-yl]-(2-methyl-5-nitro-phenyl)-amine;
Compound 145 [4-(3,4-Dimethoxy-phenyl)-pyrimidin-2-yl]-(3-nitro-phenyl)-amine;
Compound 146 4-Chloromethyl-N-{3-[4-(4-imidazol-1-yl-phenyl)-pyrimidin-2-ylamino]-4-methyl-phenyl}-benzamide;
Compound 147 N-[4-(3,4-Dimethoxy-phenyl)-pyrimidin-2-yl]-benzene-1,3-diamine;
Compound 148 4-Cyano-N-{3-[4-(4-imidazol-1-yl-phenyl)-pyrimidin-2-ylamino]-phenyl}-benzamide;
Compound 149 Naphthalene-2-carboxylic acid {3-[4-(4-imidazol-1-yl-phenyl)-pyrimidin-2-ylamino]-phenyl}-amide;
Compound 150 N-{3-[4-(4-Imidazol-1-yl-phenyl)-pyrimidin-2-ylamino]-phenyl}-nicotinamide;
Compound 151 N-{3-[4-(4-Imidazol-1-yl-phenyl)-pyrimidin-2-ylamino]-phenyl}-3,4,5-trimethoxy-benzamide;
Compound 152 4-Chloro-N-{3-[4-(4-imidazol-1-yl-phenyl)-pyrimidin-2-ylamino]-phenyl}-benzamide;
Compound 153 Naphthalene-2-carboxylic acid {3-[4-(3,4-dimethoxy-phenyl)-pyrimidin-2-ylamino]-4-methyl-phenyl}-amide;
Compound 154 N-{3-[4-(3,4-Dimethoxy-phenyl)-pyrimidin-2-ylamino]-4-methyl-phenyl}-4-methyl-benzamide;
Compound 155 4-Chloromethyl-N-{3-[4-(3,4-dimethoxy-phenyl)-pyrimidin-2-ylamino]-4-methyl-phenyl}-benzamide;
Compound 156 N-{3-[4-(3,4-Dimethoxy-phenyl)-pyrimidin-2-ylamino]-4-methyl-phenyl}-4-(4-methyl-piperazin-1-ylmethyl)-benzamide;
Compound 157 N-{3-[4-(4-Imidazol-1-yl-phenyl)-pyrimidin-2-ylamino]-phenyl}-4-methyl-benzamide;
Compound 158 N-{3-[4-(4-Imidazol-1-yl-phenyl)-pyrimidin-2-ylamino]-phenyl}-2-methoxy-benzamide;
Compound 159 N-{3-[4-(3,4-Dihydroxy-phenyl)-pyrimidin-2-ylamino]-4-methyl-phenyl}-4-(4-methyl-piperazin-1-ylmethyl)-benzamide;
Compound 160 4-Chloromethyl-N-{3-[4-(4-imidazol-1-yl-phenyl)-pyrimidin-2-ylamino]-phenyl}-benzamide;
Compound 161 4-Chloro-N-{3-[4-(3,4-dimethoxy-phenyl)-pyrimidin-2-ylamino]-4-methyl-phenyl}-benzamide;
Compound 162 N-{3-[4-(3,4-Dimethoxy-phenyl)-pyrimidin-2-ylamino]-4-methyl-phenyl}-3,4,5-trimethoxy-benzamide;
Compound 163 N-{3-[4-(3,4-Dimethoxy-phenyl)-pyrimidin-2-yl]}-4-methyl-benzene-1,3-diamine;
Compound 164 4-Cyano-N-{3-[4-(3,4-dimethoxy-phenyl)-pyrimidin-2-ylamino]-4-methyl-phenyl}-benzamide;
Compound 165 N-{3-[4-(3,4-Dimethoxy-phenyl)-pyrimidin-2-ylamino]-4-methyl-phenyl}-nicotinamide;
Compound 166 N-{3-[4-(3,4-Dimethoxy-phenyl)-pyrimidin-2-ylamino]-4-methyl-phenyl}-2-methoxy-benzamide;
Compound 167 N-(3-Methyl-isoxazolo[5,4-d]pyrimidin-4-yl)-N′-(4-pyridin-3-yl-pyrimidin-2-yl)-benzene-1,3-diamine;
Compound 168 N-(3-Methyl-isoxazolo[5,4-d]pyrimidin-4-yl)-N′-(4-pyridin-4-yl-pyrimidin-2-yl)-benzene-1,3-diamine;
Compound 169 5-(1-Imino-ethyl)-6-[4-(4-pyridin-4-yl-pyrimidin-2-ylamino)-phenylamino]-3H-pyrimidin-4-one;
Compound 170 N-(3-Methyl-isoxazolo[5,4-d]pyrimidin-4-yl)-N′-(4-pyridin-4-yl-pyrimidin-2-yl)-benzene-1,4-diamine;
Compound 171 2-(4-Methyl-piperazin-1-yl)-N-[4-(4-pyridin-4-yl-pyrimidin-2-ylamino)-phenyl]-acetamide;
Compound 172 4-{[4-(4-Pyridin-4-yl-pyrimidin-2-ylamino)-phenylcarbamoyl]-methyl}-piperazine-1-carboxylic acid ethyl ester;
Compound 173 2-Morpholin-4-yl-N-[4-(4-pyridin-4-yl-pyrimidin-2-ylamino)-phenyl]-acetamide;
Compound 174 1-{[4-(4-Pyridin-4-yl-pyrimidin-2-ylamino)-phenylcarbamoyl]-methyl}-piperidine-4-carboxylic acid ethyl ester;
Compound 175 2-Chloro-N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-acetamide;
Compound 176 4-Methyl-N-[1-(3-methyl-isoxazolo[5,4-d]pyrimidin-4-yl)]-N′-[3-(4-pyridin-3-yl-pyrimidin-2-yl)]-benzene-1,3-diamine;
Compound 177 5-(1-Imino-ethyl)-6-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenylamino]-pyrimidin-4-ol;
Compound 178 5-(1-Imino-ethyl)-6-[4-methyl-3-(4-pyridin-4-yl-pyrimidin-2-ylamino)-phenylamino]-pyrimidin-4-ol;
Compound 179 [1,8]Naphthyridine-2-carboxylic acid [4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-amide;
Compound 180 2-Chloro-N-[4-methyl-3-(4-pyridin-2-yl-pyrimidin-2-ylamino)-phenyl]-acetamide;
Compound 181 5-(1-Imino-ethyl)-6-[3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenylamino]-pyrimidin-4-ol;
Compound 182 4-(4-Methyl-piperazin-1-ylmethyl)-N-[4-(4-pyridin-2-yl-pyrimidin-2-ylamino)-phenyl]-benzamide;
Compound 183 4-{[3-(4-Pyridin-3-yl-pyrimidin-2-ylamino)-phenylcarbamoyl]-methyl}-piperazine-1-carboxylic acid ethyl ester;
Compound 184 2-Morpholin-4-yl-N-[3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-acetamide;
Compound 185 1-{[3-(4-Pyridin-3-yl-pyrimidin-2-ylamino)-phenylcarbamoyl]-methyl}-piperidine-4-carboxylic acid ethyl ester;
Compound 186 2-(4-Methyl-piperazin-1-yl)-N-[4-(4-pyridin-2-yl-pyrimidin-2-ylamino)-phenyl]-acetamide;
Compound 187 2-Morpholin-4-yl-N-[4-(4-pyridin-2-yl-pyrimidin-2-ylamino)-phenyl]-acetamide;
Compound 188 4-{[4-(4-Pyridin-2-yl-pyrimidin-2-ylamino)-phenylcarbamoyl]-methyl}-piperazine-1-carboxylic acid ethyl ester;
Compound 189 1-{[4-(4-Pyridin-2-yl-pyrimidin-2-ylamino)-phenylcarbamoyl]-methyl}-piperidine-4-carboxylic acid ethyl ester;
Compound 190 2-(4-Methyl-piperazin-1-yl)-N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-acetamide;
Compound 191 1-{[4-Methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenylcarbamoyl]-methyl}-piperidine-4-carboxylic acid ethyl ester;
Compound 192 4-{[4-Methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenylcarbamoyl]-methyl}-piperazine-1-carboxylic acid ethyl ester;
Compound 193 N-[4-Methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-2-morpholin-4-yl-acetamide;
Compound 194 4-Methyl-N-[1-(3-methyl-isoxazolo[5,4-d]pyrimidin-4-yl)]-N′-[3-(4-pyridin-4-yl-pyrimidin-2-yl)]-benzene-1,3-diamine;
Compound 195 2-(4-Methyl-piperazin-1-yl)-N-[4-methyl-3-(4-pyridin-4-yl-pyrimidin-2-ylamino)-phenyl]-acetamide;
Compound 196 N-[4-Methyl-3-(4-pyridin-4-yl-pyrimidin-2-ylamino)-phenyl]-2-morpholin-4-yl-acetamide;
Compound 197 3,4,5-Trimethoxy-N-[4-(4-pyridin-4-yl-pyrimidin-2-ylamino)-phenyl]-benzamide;
Compound 198 2-Methoxy-N-[4-(4-pyridin-4-yl-pyrimidin-2-ylamino)-phenyl]-benzamide;
Compound 199 N-[4-(4-Pyridin-4-yl-pyrimidin-2-ylamino)-phenyl]-nicotinamide;
Compound 200 Naphthalene-2-carboxylic acid [4-(4-pyridin-4-yl-pyrimidin-2-ylamino)-phenyl]-amide;
Compound 201 4-Chloro-N-[4-(4-pyridin-4-yl-pyrimidin-2-ylamino)-phenyl]-benzamide;
Compound 202 1-{[4-Methyl-3-(4-pyridin-4-yl-pyrimidin-2-ylamino)-phenylcarbamoyl]-methyl}-piperidine-4-carboxylic acid ethyl ester;
Compound 203 Thiophene-2-sulfonic acid [4-(4-pyridin-4-yl-pyrimidin-2-ylamino)-phenyl]-amide;
Compound 204 4-{[4-Methyl-3-(4-pyridin-4-yl-pyrimidin-2-ylamino)-phenylcarbamoyl]-methyl}-piperazine-1-carboxylic acid ethyl ester;
Compound 205 4-Bromo-N-[4-(4-pyridin-4-yl-pyrimidin-2-ylamino)-phenyl]-benzamide;
Compound 206 2,3,4,5,6-Pentafluoro-N-[4-(4-pyridin-4-yl-pyrimidin-2-ylamino)-phenyl]-benzamide;
Compound 207 2-(4-Methyl-piperazin-1-yl)-N-[4-methyl-3-(4-pyridin-2-yl-pyrimidin-2-ylamino)-phenyl]-acetamide;
Compound 208 N-[4-Methyl-3-(4-pyridin-2-yl-pyrimidin-2-ylamino)-phenyl]-2-morpholin-4-yl-acetamide;
Compound 209 4-Chloro-N-[4-(4-pyridin-4-yl-pyrimidin-2-ylamino)-phenyl]-benzenesulfonamide;
Compound 210 Naphthalene-2-sulfonic acid [4-(4-pyridin-4-yl-pyrimidin-2-ylamino)-phenyl]-amide;
Compound 211 4-Methyl-N-[3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-benzenesulfonamide;
Compound 212 [1,8]Naphthyridine-2-carboxylic acid [4-methyl-3-(4-pyridin-4-yl-pyrimidin-2-ylamino)-phenyl]-amide;
Compound 213 4-(4-Methyl-piperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-4-yl-pyrimidin-2-ylamino)-phenyl]-benzamide;
Compound 214 1-{[4-Methyl-3-(4-pyridin-2-yl-pyrimidin-2-ylamino)-phenylcarbamoyl]-methyl}-piperidine-4-carboxylic acid ethyl ester;
Compound 215 4-{[4-Methyl-3-(4-pyridin-2-yl-pyrimidin-2-ylamino)-phenylcarbamoyl]-methyl}-piperazine-1-carboxylic acid ethyl ester;
Compound 216 4-Chloro-N-[4-(4-pyridin-2-yl-pyrimidin-2-ylamino)-phenyl]-benzenesulfonamide;
Compound 217 Naphthalene-2-sulfonic acid [4-(4-pyridin-2-yl-pyrimidin-2-ylamino)-phenyl]-amide;
Compound 218 4-Chloro-N-[4-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-benzenesulfonamide,
Compound 219 Naphthalene-2-sulfonic acid [4-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-amide;
Compound 220 2-Methoxy-N-[4-methyl-3-(4-pyridin-4-yl-pyrimidin-2-ylamino)-phenyl]-benzamide;
Compound 221 N-(3-Methyl-isoxazolo[5,4-d]pyrimidin-4-yl)-N′-(4-pyridin-2-yl-pyrimidin-2-yl)-benzene-1,4-diamine;
Compound 222 Naphthalene-2-carboxylic acid [4-methyl-3-(4-pyridin-4-yl-pyrimidin-2-ylamino)-phenyl]-amide;
Compound 223 N-[4-Methyl-3-(4-pyridin-4-yl-pyrimidin-2-ylamino)-phenyl]-benzamide;
Compound 224 2-(4-Methyl-piperazin-1-yl)-N-[3-(4-pyridin-4-yl-pyrimidin-2-ylamino)-phenyl]-acetamide;
Compound 225 4-Methyl-N-[4-methyl-3-(4-pyridin-4-yl-pyrimidin-2-ylamino)-phenyl]-benzamide;
Compound 226 2-Morpholin-4-yl-N-[3-(4-pyridin-4-yl-pyrimidin-2-ylamino)-phenyl]-acetamide;
Compound 227 Naphthalene-2-sulfonic acid [4-methyl-3-(4-pyridin-4-yl-pyrimidin-2-ylamino)-phenyl]-amide;
Compound 228 1-{[3-(4-Pyridin-4-yl-pyrimidin-2-ylamino)-phenylcarbamoyl]-methyl}-piperidine-4-carboxylic acid ethyl ester;
Compound 229 4-{[3-(4-Pyridin-4-yl-pyrimidin-2-ylamino)-phenylcarbamoyl]-methyl}-piperazine-1-carboxylic acid ethyl ester;
Compound 230 1-{[3-(4-Pyridin-4-yl-pyrimidin-2-ylamino)-phenylcarbamoyl]-methyl}-piperidine-4-carboxylic acid;
Compound 231 Cyclohexanecarboxylic acid [4-methyl-3-(4-pyridin-4-yl-pyrimidin-2-ylamino)-phenyl]-amide;
Compound 232 N,N′-Bis-[4-(3,4-dimethoxy-phenyl)-pyrimidin-2-yl]-benzene-1,3-diamine;
Compound 233 N-[4-(4-Imidazol-1-yl-phenyl)-pyrimidin-2-yl]-N′-(3-methyl-isoxazolo[5,4-d]pyrimidin-4-yl)-benzene-1,3-diamine;
Compound 234 3-Fluoro-N-{3-[4-(4-imidazol-1-yl-phenyl)-pyrimidin-2-ylamino]-phenyl}-benzamide;
Compound 235 N-{3-[4-(3,4-Dimethoxy-phenyl)-pyrimidin-2-ylamino]-4-methyl-phenyl}-3-fluoro-benzamide;
Compound 236 N-{3-[4-(4-Imidazol-1-yl-phenyl)-pyrimidin-2-ylamino]-phenyl}-4-(4-methyl-piperazin-1-ylmethyl)-benzamide;
Compound 237 N-{3-[4-(3,4-Dimethoxy-phenyl)-pyrimidin-2-yl]}-4-methyl-N′-[1-(3-methyl-isoxazolo[5,4-d]pyrimidin-4-yl)]-benzene-1,3-diamine;
Compound 238 3-Fluoro-N-{3-[4-(4-imidazol-1-yl-phenyl)-pyrimidin-2-ylamino]-4-methyl-phenyl}-benzamide;
Compound 239 N-{3-[4-(3,4-Dimethoxy-phenyl)-pyrimidin-2-ylamino]-phenyl}-3-fluoro-benzamide;
Compound 240 N-{3-[4-(4-Imidazol-1-yl-phenyl)-pyrimidin-2-yl]}-4-methyl-N′-[1-(3-methyl-isoxazolo[5,4-d]pyrimidin-4-yl)]-benzene-1,3-diamine;
Compound 241 4-Chloro-N-{3-[4-(3,4-dimethoxy-phenyl)-pyrimidin-2-ylamino]-phenyl}-benzamide;
Compound 242 N-{3-[4-(3,4-Dimethoxy-phenyl)-pyrimidin-2-ylamino]-phenyl}-4-methyl-benzamide;
Compound 243 N-{3-[4-(3,4-Dimethoxy-phenyl)-pyrimidin-2-ylamino]-phenyl}-3,4,5-trimethoxy-benzamide;
Compound 244 4-Cyano-N-{3-[4-(3,4-dimethoxy-phenyl)-pyrimidin-2-ylamino]-phenyl}-benzamide;
Compound 245 4-Chloromethyl-N-{3-[4-(3,4-dimethoxy-phenyl)-pyrimidin-2-ylamino]-phenyl}-benzamide;
Compound 246 Naphthalene-2-carboxylic acid {3-[4-(3,4-dimethoxy-phenyl)-pyrimidin-2-ylamino]-phenyl}-amide;
Compound 247 N-{3-[4-(3,4-Dimethoxy-phenyl)-pyrimidin-2-ylamino]-phenyl}-2-methoxy-benzamide;
Compound 248 N-{3-[4-(3,4-Dimethoxy-phenyl)-pyrimidin-2-ylamino]-phenyl}-nicotinamide;
Compound 249 N-{3-[4-(3,4-Dimethoxy-phenyl)-pyrimidin-2-ylamino]-phenyl}-4-(4-methyl-piperazin-1-ylmethyl)-benzamide;
Compound 250 N-[4-(3,4-Dimethoxy-phenyl)-pyrimidin-2-yl]-N′-(3-methyl-isoxazolo[5,4-d]pyrimidin-4-yl)-benzene-1,3-diamine;
Compound 251 Isoquinoline-5-sulfonic acid {3-[4-(3,4-dimethoxy-phenyl)-pyrimidin-2-ylamino]-4-methyl-phenyl}-amide;
Compound 252 N-{3-[4-(4-Imidazol-1-yl-phenyl)-pyrimidin-2-ylamino]-4-methyl-phenyl}-4-(4-methyl-piperazin-1-ylmethyl)-benzamide;
Compound 253 (4-Benzo[1,3]dioxol-5-yl-pyrimidin-2-yl)-(2-methyl-5-nitro-phenyl)-amine;
Compound 254 4-(4-Methyl-piperazin-1-ylmethyl)-N-[4-(4-pyridin-4-yl-pyrimidin-2-ylamino)-phenyl]-benzamide;
Compound 255 N-[4-(4-Imidazol-1-yl-phenyl)-pyrimidin-2-yl]-benzene-1,4-diamine;
Compound 256 N-[4-(3,4-Dimethoxy-phenyl)-pyrimidin-2-yl]-benzene-1,4-diamine;
Compound 257 Naphthalene-2-carboxylic acid {4-[4-(4-imidazol-1-yl-phenyl)-pyrimidin-2-ylamino]-phenyl}-amide;
Compound 258 (3-Chloro-phenyl)-(4-pyridin-4-yl-pyrimidin-2-yl)-amine;
Compound 259 [1,8]Naphthyridine-2-carbothioic acid [4-methyl-3-(4-pyridin-4-yl-pyrimidin-2-ylamino)-phenyl]-amide;
Compound 260 4-Methyl-N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-benzenesulfonamide;
Compound 261 3-Chloro-N-[4-methyl-3-(4-pyridin-4-yl-pyrimidin-2-ylamino)-phenyl]-propionamide;
Compound 262 3-(4-Methyl-piperazin-1-yl)-N-[4-methyl-3-(4-pyridin-4-yl-pyrimidin-2-ylamino)-phenyl]-propionamide;
Compound 263 4-{2-[4-Methyl-3-(4-pyridin-4-yl-pyrimidin-2-ylamino)-phenylcarbamoyl]-ethyl}-piperazine-1-carboxylic acid ethyl ester;
Compound 264 2-(4-Methyl-piperazin-1-yl)-N-[3-(4-pyridin-2-yl-pyrimidin-2-ylamino)-phenyl]-acetamide;
Compound 265 2-Morpholin-4-yl-N-[3-(4-pyridin-2-yl-pyrimidin-2-ylamino)-phenyl]-acetamide;
Compound 266 N-[4-Methyl-3-(4-pyridin-2-yl-pyrimidin-2-ylamino)-phenyl]-nicotinamide;
Compound 267 1-{[3-(4-Pyridin-2-yl-pyrimidin-2-ylamino)-phenylcarbamoyl]-methyl}-piperidine-4-carboxylic acid ethyl ester;
Compound 268 4-{[3-(4-Pyridin-2-yl-pyrimidin-2-ylamino)-phenylcarbamoyl]-methyl}-piperazine-1-carboxylic acid ethyl ester;
Compound 269 Naphthalene-2-carboxylic acid [4-methyl-3-(4-pyridin-2-yl-pyrimidin-2-ylamino)-phenyl]-amide;
Compound 270 4-Bromo-N-[4-methyl-3-(4-pyridin-2-yl-pyrimidin-2-ylamino)-phenyl]-benzamide;
Compound 271 1-{[3-(4-Pyridin-2-yl-pyrimidin-2-ylamino)-phenylcarbamoyl]-methyl}-piperidine-4-carboxylic acid;
Compound 272 4-Methyl-N-[4-methyl-3-(4-pyridin-2-yl-pyrimidin-2-ylamino)-phenyl]-benzamide;
Compound 273 Naphthalene-2-sulfonic acid [4-methyl-3-(4-pyridin-2-yl-pyrimidin-2-ylamino)-phenyl]-amide;
Compound 274 4-Chloromethyl-N-[4-methyl-3-(4-pyridin-2-yl-pyrimidin-2-ylamino)-phenyl]-benzamide;
Compound 275 2-Methoxy-N-[4-methyl-3-(4-pyridin-2-yl-pyrimidin-2-ylamino)-phenyl]-benzamide;
Compound 276 4-(4-Methyl-piperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-2-yl-pyrimidin-2-ylamino)-phenyl]-benzamide;
Compound 277 4-Fluoro-N-[4-methyl-3-(4-pyridin-2-yl-pyrimidin-2-ylamino)-phenyl]-benzenesulfonamide;
Compound 278 Cyclopentanecarboxylic acid [4-methyl-3-(4-pyridin-2-yl-pyrimidin-2-ylamino)-phenyl]-amide;
Compound 279 3-{4-[2-(3-Chloro-phenylamino)-pyrimidin-4-yl]-pyridin-2-ylamino}-propan-1-ol;
Compound 280 Isoquinoline-5-sulfonic acid {3-[4-(4-imidazol-1-yl-phenyl)-pyrimidin-2-ylamino]-4-methyl-phenyl}-amide;
Compound 281 (2-Methyl-5-nitro-phenyl)-(4-pyridin-3-yl-pyrimidin-2-yl)-amine;
Compound 282 (3-Chloro-phenyl)-[4-(2-chloro-pyridin-4-yl)-pyrimidin-2-yl]-amine;
Compound 283 4-Chloromethyl-N-[3-(4-pyridin-4-yl-pyrimidin-2-ylamino)-phenyl]-benzamide;
Compound 284 Thiophene-2-sulfonic acid {3-[4-(3,4-dimethoxy-phenyl)-pyrimidin-2-ylamino]-4-methyl-phenyl}-amide;
Compound 285 4-(4-Methyl-piperazin-1-ylmethyl)-N-[3-(4-pyridin-4-yl-pyrimidin-2-ylamino)-phenyl]-benzamide;
Compound 286 N-{1-{5-[2-(3,4,5-Trimethoxy-phenylamino)-pyrimidin-4-yl]-pyridin-2-yl}}-ethane-1,2-diamine;
Compound 287 [4-(6-Dimethylamino-pyridin-3-yl)-pyrimidin-2-yl]-(3,4,5-trimethoxy-phenyl)-amine;
Compound 288 2,2-Dimethyl-N-{3-[2-(2-methyl-5-nitro-phenylamino)-pyrimidin-4-yl]-pyridin-4-yl}-propionamide;
Compound 289 [4-(4-Amino-pyridin-3-yl)-pyrimidin-2-yl]-(2-methyl-5-nitro-phenyl)-amine;
Compound 290 3-{5-[2-(3-Chloro-phenylamino)-pyrimidin-4-yl]-pyridin-2-ylamino}-propan-1-ol;
Compound 291 (3-Chloro-phenyl)-[4-(6-chloro-pyridin-3-yl)-pyrimidin-2-yl]-amine;
Compound 294 [4-(1-Oxy-pyridin-4-yl)-pyrimidin-2-yl]-(3-trifluoromethyl-phenyl)-amine;
Compound 295 3-(4-Pyridin-4-yl-pyrimidin-2-ylamino)-benzoic acid ethyl ester;
Compound 296 3-[4-(1-Oxy-pyridin-4-yl)-pyrimidin-2-ylamino]-benzoic acid ethyl ester;
Compound 297 3-{4-[2-(3-Trifluoromethyl-phenylamino)-pyrimidin-4-yl]-pyridin-2-ylamino}-propan-1-ol;
Compound 298 2-{4-[2-(3-Trifluoromethyl-phenylamino)-pyrimidin-4-yl]-pyridin-2-ylamino}-ethanol;
Compound 299 5-{4-[2-(3-Trifluoromethyl-phenylamino)-pyrimidin-4-yl]-pyridin-2-ylamino}-pentan-1-ol;
Compound 300 {4-[2-(3-Imidazol-1-yl-propylamino)-pyridin-4-yl]-pyrimidin-2-yl}-(3-trifluoromethyl-phenyl)-amine;
Compound 301 (4-{2-[3-(4-Methyl-piperazin-1-yl)-propylamino]-pyridin-4-yl}-pyrimidin-2-yl)-(3-trifluoromethyl-phenyl)-amine;
Compound 302 3-(4-Pyridin-4-yl-pyrimidin-2-ylamino)-benzoic acid;
Compound 303 N-(3-Hydroxy-propyl)-3-{4-[2-(3-hydroxy-propylamino)-pyridin-4-yl]-pyrimidin-2-ylamino}-benzamide;
Compound 304 3-[4-(2-Chloro-pyridin-4-yl)-pyrimidin-2-ylamino]-benzoic acid;
Compound 305 3-{4-[2-(3-Hydroxy-propylamino)-pyridin-4-yl]-pyrimidin-2-ylamino}-benzoic acid;
Compound 306 1-[3-(4-Pyridin-4-yl-pyrimidin-2-ylamino)-benzoyl]-piperidine-4-carboxylic acid ethyl ester;
Compound 307 3-{4-[2-(3-Hydroxy-propylamino)-pyridin-4-yl]-pyrimidin-2-ylamino}-benzoic acid methyl ester;
Compound 308 N-(4,4-Diethoxy-butyl)-3-(4-pyridin-4-yl-pyrimidin-2-ylamino)-benzamide;
Compound 309 [4-(2-Chloro-pyridin-4-yl)-pyrimidin-2-yl]-(3-methylsulfanyl-phenyl)-amine;
Compound 310 2-{4-[2-(3-Methylsulfanyl-phenylamino)-pyrimidin-4-yl]-pyridin-2-ylamino}-ethanol;
Compound 311 5-{4-[2-(3-Methylsulfanyl-phenylamino)-pyrimidin-4-yl]-pyridin-2-ylamino}-pentan-1-ol; and
Compound 312 3-{4-[2-(3-Methylsulfanyl-phenylamino)-pyrimidin-4-yl]-pyridin-2-ylamino}-propan-1-ol;

### Claim 7

(canceled)

### Claim 8 (depends on 1)

A method for inhibiting the production of a kinase and/or a phosphatase in an individual in need thereof, comprising administering to the individual a pharmaceutical composition comprising a compound according to claim 1, wherein said individual is suffering from a disease or disorder which can be cured or relieved by the inhibition of said kinase and/or phosphatase.

### Claim 9 (depends on 8)

The method according to claim 8, wherein the kinase and/or phosphatase is selected from the group consisting of Abl, Akt, c-kit, EGF-R, GSK3β, JNK, Lck, PDGF-Rβ, PknG, and ROCK2.

### Claim 10 (depends on 1)

A method for treating an individual suffering from a disease or disorder selected from the group consisting of cell proliferation disorders, cancer, leukemia, erectile dysfunction, cardiovascular diseases and disorders, inflammatory diseases, transplant rejection, immunological diseases, neuroimmunological diseases, autoimmune diseases, infective diseases including opportunistic infections, prion diseases, neurodegenerative disorders and/or neuro-degeneration, the method comprising administering to said individual a pharmaceutical composition comprising a compound according to claim 1 or a pharmaceutically-acceptable salt thereof.

### Claim 11 (depends on 10)

The method according to claim 10, wherein the proliferation disorder or cancer is selected from the group consisting of adenocarcinoma, choroidal melanoma, acute leukemia, acoustic neurinoma, ampullary carcinoma, anal carcinoma, astrocytoma, basal cell carcinoma, pancreatic cancer, desmoid tumor, bladder cancer, bronchial carcinoma, breast cancer, Burkitt's lymphoma, corpus cancer, CUP-syndrome (carcinoma of unknown primary), colorectal cancer, small intestine cancer, small intestinal tumors, ovarian cancer, endometrial carcinoma, ependymoma, epithelial cancer types, Ewing's tumors, gastrointestinal tumors, gallbladder cancer, gall bladder carcinomas, uterine cancer, cervical cancer, glioblastomas, gynecologic tumors, ear, nose and throat tumors, hematologic neoplasias, hairy cell leukemia, urethral cancer, skin cancer, brain tumors (gliomas), brain metastases, testicle cancer, hypophysis tumor, carcinoids, Kaposi's sarcoma, laryngeal cancer, germ cell tumor, bone cancer, colorectal carcinoma, head and neck tumors (tumors of the ear, nose and throat area), colon carcinoma, craniopharyngiomas, oral cancer (cancer in the mouth area and on lips), liver cancer, liver metastases, leukemia, eyelid tumor, lung cancer, lymph node cancer (Hodgkin's/Non-Hodgkin's), lymphomas, stomach cancer, malignant melanoma, malignant neoplasia, malignant tumors gastrointestinal tract, breast carcinoma, rectal cancer, medulloblastomas, melanoma, meningiomas, Hodgkin's disease, mycosis fungoides, nasal cancer, neurinoma, neuroblastoma, kidney cancer, renal cell carcinomas, non-Hodgkin's lymphomas, oligodendroglioma, esophageal carcinoma, osteolytic carcinomas and osteoplastic carcinomas, osteosarcomas, ovarial carcinoma, pancreatic carcinoma, penile cancer, plasmocytoma, prostate cancer, pharyngeal cancer, rectal carcinoma, retinoblastoma, vaginal cancer, thyroid carcinoma, Schneeberger disease, esophageal cancer, spinalioms, T-cell lymphoma (mycosis fungoides), thymoma, tube carcinoma, eye tumors, urethral cancer, urologic tumors, urothelial carcinoma, vulva cancer, wart appearance, soft tissue tumors, soft tissue sarcoma, Wilm's tumor, cervical carcinoma, and tongue cancer.

### Claim 12 (depends on 10)

The method according to claim 10, wherein the cardiovascular disease or disorder is selected from the group consisting of aneurysm, stable angina, unstable angina, angina pectoris, angioneurotic edema, stenosis, restenosis, aortic valve stenosis, aortic aneurysm, arrhythmia, arrhythmogenic right ventricular dysplasia, arteriosclerosis, arteriovenous malformations, atrial fibrillation, Behcet Syndrome, bradycardia, cardiac tamponade, cardiomegaly, congestive cardiomyopathy, hypertrophic cardiomyopathy, restrictive cardiomyopathy, carotid stenosis, cerebral hemorrhage, Churg-Strauss Syndrome, diabetes, Ebstein's Anomaly, Eisenmenger Complex, cholesterol embolism, bacterial endocarditis, fibromuscular dysplasia, congenital heart defects, heart diseases, congestive heart failure, heart valve diseases, heart attack, epidural hematoma, hematoma, subdural, Hippel-Lindau Disease, hyperemia, hypertension, pulmonary hypertension, left ventricular hypertrophy, right ventricular hypertrophy, hypoplastic left heart syndrome, hypotension, intermittent claudication, ischemic heart disease, Klippel-Trenaunay-Weber Syndrome, lateral medullary syndrome, long QT syndrome mitral valve prolapse, moyamoya disease, mucocutaneous lymph node syndrome, myocardial infarction, myocardial ischemia, myocarditis, pericarditis, peripheral vascular diseases, phlebitis, polyarteritis nodosa, pulmonary atresia, Raynaud Disease, Sneddon Syndrome, superior vena cava syndrome, syndrome X, tachycardia, Takayasu's Arteritis, hereditary hemorrhagic telangiectasia, telangiectasis, temporal Arteritis, tetralogy of fallot, thromboangiitis obliterans, thrombosis, thromboembolism, tricuspid atresia, varicose veins, vascular diseases, vasculitis, vasospasm, ventricular fibrillation, Williams Syndrome, peripheral vascular disease, varicose veins and leg ulcers, deep vein thrombosis, and Wolff-Parkinson-White Syndrome.

### Claim 13 (depends on 10)

The method according to claim 10, wherein the inflammatory disease is selected from the group consisting of diseases which are associated with overexpression or overproduction of the protein amyloid A, including arthritides, rheumatoid arthritis, asthma, lupus, bleeding disorders (thrombocytopenia), chronic inflammatory lung diseases, atherosclerosis, kidney inflammation (nephritis), psoriasis, allergies, Crohn's disease, ischemia/reperfusion injury, endotoxemic liver injury, inflammatory bowel disease, tuberculosis, chronic infections, familial Mediterranean fever, interstitial cystitis and skin sunburn.

### Claim 14 (depends on 10)

The method according to claim 10, wherein the neurodegenerative disorders or neurodegeneration is selected from the group consisting of Alzheimer disease, Parkinson disease, Huntington disease, amyotrophic lateral sclerosis, AIDS-related dementia, retinitis pigmentosa, spinal muscular atrophy and cerebrellar degeneration, fragile X-associated tremor/ataxia syndrome (FXTAS), progressive supranuclear palsy (PSP), and striatonigral degeneration (SND), which is included with olivopontocerebellear degeneration (OPCD), and Shy Drager syndrome (SDS) in a syndrome known as multiple system atrophy (MSA).

### Claim 15 (depends on 10)

The method according to claim 10, wherein the immunological disease, neuroimmunological disease, and/or autoimmune disease is selected from the group consisting of asthma, diabetes, rheumatic diseases, AIDS, rejection of transplanted organs and tissues, rhinitis, chronic obstructive pulmonary diseases, osteoporisis, ulcerative colitis, sinusitis, lupus erythematosus, recurrent infections, atopic dermatitis/eczema and occupational allergies, food allergies, drug allergies, severe anaphylactic reactions, anaphylaxis, manifestations of allergic diseases, primary immunodeficiencies, antibody deficiency states, cell mediated immunodeficiencies, severe combined immunodeficiency, DiGeorge syndrome, Hyper-IgE syndrome, Wiskott-Aldrich syndrome, ataxia-telangiectasia, immune mediated cancers, white cell defects, autoimmune diseases, systemic lupus erythematosus, rheumatoid arthritis (RA), multiple sclerosis (MS), immune-mediated or Type 1 Diabetes Mellitus, immune mediated glomerulonephritis, scleroderma, pernicious anemia, alopecia, pemphigus, pemphigus vulgaris, myasthenia gravis, inflammatory bowel diseases, Crohn's disease, psoriasis, autoimmune thyroid diseases, Hashimoto's disease, dermatomyositis, goodpastture syndrome, myasthenia gravis pseudoparalytica, ophtalmia sympatica, phakogene uveitis, chronical aggressive hepatitis, primary billiary cirrhosis, autoimunehemolytic anemy, and Werlof disease.

### Claim 16 (depends on 10)

The method according to claim 10, wherein the infective disease including opportunistic infection is selected from the group consisting of AIDS, Alveolar Hydatid Disease (AHD, Echinococcosis), Amebiasis (Entamoeba histolytica Infection), Angiostrongylus Infection, Anisakiasis, Anthrax, Babesiosis (Babesia Infection), Balantidium Infection (Balantidiasis), Baylisascaris Infection (Raccoon Roundworm), Bilharzia (Schistosomiasis), Blastocystis hominis Infection (Blastomycosis), Boreliosis, Botulism, Brainerd Diarrhea, Brucellosis, BSE (Bovine Spongiform Encephalopathy), Candidiasis, Capillariasis (Capillaria Infection), CFS (Chronic Fatigue Syndrome), Chagas Disease (American Trypanosomiasis), Chickenpox (Varicella-Zoster virus), Chlamydia pneumoniae Infection, Cholera, Chronic Fatigue Syndrome, CJD (Creutzfeldt-Jakob Disease), Clonorchiasis (Clonorchis Infection), CLM (Cutaneous Larva Migrans, Hookworm Infection), Coccidioidomycosis, Conjunctivitis, Coxsackievirus A16 (Hand, Foot and Mouth Disease), Cryptococcosis, Cryptosporidium Infection (Cryptosporidiosis), Culex mosquito (Vector of West Nile Virus), Cutaneous Larva Migrans (CLM), Cyclosporiasis (Cyclospora Infection), Cysticercosis (Neurocysticercosis), Cytomegalovirus Infection, Dengue/Dengue Fever, Dipylidium Infection (Dog and Cat Flea Tapeworm), Ebola Virus Hemorrhagic Fever, Echinococcosis (Alveolar Hydatid Disease), Encephalitis, Entomoeba coli Infection, Entomoeba dispar Infection, Entomoeba hartmanni Infection, Entomoeba histolytica Infection (Amebiasis), Entomoeba polecki Infection, Enterobiasis (Pinworm Infection), Enterovirus Infection (Non-Polio), Epstein-Barr Virus Infection, Escherichia coli Infection, Foodborne Infection, Foot and mouth Disease, Fungal Dermatitis, Gastroenteritis, Group A streptococcal Disease, Group B streptococcal Disease, Hansen's Disease (Leprosy), Hantavirus Pulmonary Syndrome, Head Lice Infestation (Pediculosis), Helicobacter pylori Infection, Hematologic Disease, Hendra Virus Infection, Hepatitis (HCV, HBV), Herpes Zoster (Shingles), HIV Infection, Human Ehrlichiosis, Human Parainfluenza Virus Infection, Influenza, Isosporiasis (Isospora Infection), Lassa Fever, Leishmaniasis, Kala-azar (Kala-azar, Leishmania Infection), Leprosy, Lice (Body lice, Head lice, Pubic lice), Lyme Disease, Malaria, Marburg Hemorrhagic Fever, Measles, Meningitis, Mosquito-borne Diseases, Mycobacterium avium Complex (MAC) Infection, Naegleria Infection, Nosocomial Infections, Nonpathogenic Intestinal Amebae Infection, Onchocerciasis (River Blindness), Opisthorciasis (Opisthorcis Infection), Parvovirus Infection, Plague, PCP (Pneumocystis carinii Pneumonia), Polio, Q Fever, Rabies, Respiratory Syncytial Virus (RSV) Infection, Rheumatic Fever, Rift Valley Fever, River Blindness (Onchocerciasis), Rotavirus Infection, Roundworms Infection, Salmonellosis, Salmonella Enteritidis, Scabies, Shigellosis, Shingles, Sleeping Sickness, Smallpox, Streptococcal Infection, Tapeworm Infection (Taenia Infection), Tetanus, Toxic Shock Syndrome, Tuberculosis, Ulcers (Peptic Ulcer Disease), Valley Fever, Vibrio parahaemolyticus Infection, Vibrio vulnificus Infection, Viral Hemorrhagic Fever, Warts, Waterborne infectious Diseases, West Nile Virus Infection (West Nile Encephalitis), Whooping Cough, Yellow Fever.

### Claim 17 (depends on 10)

The method according to claim 10, wherein the prion diseases is selected from the group consisting of Scrapie, TME, CWD, BSE, CJD, vCJD, GSS, FFI, Kuru, and Alpers Syndrome.

### Claim 18 (depends on 10)

The method according to claim 10, wherein the transplant rejection is selected from the group consisting of heart transplant rejection, heart-lung transplant rejection, lung transplant rejection, liver transplant rejection, kidney transplant rejection, pancreas transplant rejection, spleen transplant rejection, skin transplant rejection, tissue transplant rejection, bone marrow transplant rejection, spinal marrow transplant rejection, hormone producing glands transplant rejection, gonads and gonadal gland transplant rejection, graft-versus-host-diseases and host-versus-graft-diseases.

### Claim 19 (depends on 1)

A pharmaceutical composition comprising at least one compound according to claim 1 and a pharmaceutically acceptable carrier, excipient, or diluent.

### Claim 20 (depends on 19)

The pharmaceutical composition according to claim 19, wherein the pharmaceutical composition is formulated as pills, tablets, tabs, film tablets, coated tablets, dragees, multi-layer tablets, capsules, powders, granulates, deposits, sustained release formulations, controlled release formulations, mini- and micro-formulations, nano-formulations, liposomal formulations, dispersions, suspensions, liquid formulations, drops, injections, sprays, ointments, creams, pastes, syrup, lotions, or gels.

### Claim 21 (depends on 1)

A method for detecting prion infections and/or prion diseases in a sample from an individual comprising:
a) providing a sample from an individual; and
b) adding to said sample at least one compound according to claim 1 or a pharmaceutically active salt thereof; and
c) detecting activity in said sample of the human cellular protein kinase Abl.
